Medical Bulletin 9/December/2021

Here are Top Medical stories of the day

Patients with high cholesterol and triglycerides more prone to perioperative retinal vein occlusion

Patients with high cholesterol and triglycerides who underwent spinal, cardiac or orthopedic surgery were at greater risk of waking up blind, reports a new Northwestern Medicine study.

The condition, called perioperative visual loss, is caused when a blood clot blocks the veins, an occurrence called retinal vein occlusion.

For more details, check out the full story on the link below:

Patients With High Cholesterol And Triglycerides More Prone To Perioperative Retinal Vein Occlusion

A rare case report of man having tooth in nose

Subcutaneous ianalumab safe and effective for Sjögren's syndrome

Findings from a recent trial showed ianalumab to be safe and well-tolerated in patients with moderate to severe primary Sjogren's syndrome. The study was published in the journal The Lancet on November 30, 2021.

Sjögren's syndrome is an immune system disorder characterized by dry eyes and mouth, systemic features, and reduced quality of life. Currently, there are no disease-modifying treatments. A new biologic, ianalumab (VAY736), with two modes of suppressing B cells, has previously shown preliminary efficacy.

For more details, check out the full story on the link below:

Subcutaneous Ianalumab Safe And Effective For Sjogren's Syndrome: Lancet

Psychedelics show promise in treating mental illness

One in five U.S. adults will experience a mental illness in their lifetime, according to the National Alliance of Mental Health. But standard treatments can be slow to work and cause side effects.

To find better solutions, a Virginia Tech researcher has joined a renaissance of research on a long-banned class of drugs that could combat several forms of mental illness and, in mice, have achieved long-lasting results from just one dose.

For more details, check out the full story on the link below:

Psychedelics Show Promise In Treating Mental Illness

Dietary weight loss may improve neuropathy in obese patients

Weight loss may stabilize neuropathy, according to a recent study published in the Obesity. In the study, after 2 years, successful dietary weight loss in those with severe obesity lead to stable neuropathy as measured by our primary outcome (intraepidermal nerve fiber density).

Neuropathy is a highly prevalent condition that results in pain, falls, and lower quality of life. Although diabetes has long been known to be the leading cause of neuropathy, obesity has recently emerged as an important risk factor. Furthermore, obesity is likely sufficient to cause neuropathy even in those with normal glucose control. In addition to hyperglycemia and obesity, other individual components of metabolic syndrome (hypertension, hypertriglyceridemia, and low high-density lipoprotein [HDL] cholesterol) have also been shown to be associated with neuropathy. Unfortunately, despite multiple potentially modifiable risk factors, the only established disease-modifying therapy for neuropathy is glycemic control, which prevents neuropathy to a much larger degree in type 1 than in type 2 diabetes.

For more details, check out the full story on the link below:

Dietary Weight Loss May Improve Neuropathy In Obese Patients: Study